Platelet hyperactivity in hypertensive older patients is controlled by lowering blood pressure

J Am Geriatr Soc. 1999 Aug;47(8):943-7. doi: 10.1111/j.1532-5415.1999.tb01288.x.

Abstract

Objective: Patients with hypertension tend to have a high prevalence of atherothrombotic accidents. Platelet hyperactivity is frequently associated with hypertension. Because the vascular disease associated with hypertension evolves over the years, we investigated platelet activity parameters in a population of older hypertensive patients with no other risk factors for cardiovascular disease.

Participants: We studied 34 older, nonsmoking patients (mean age 74 +/- 5 years) with uncomplicated hypertension before and after the normalization of blood pressure (BP) was achieved with the angiotensin-converting enzyme inhibitor quinapril alone or in combination with the Ca2+ antagonist nifedipine.

Measurements: Platelet aggregation, P-selectin (CD62) expression on the platelet surface, serum levels of Interleukin-1beta (IL-1beta) and of Interleukin-6 (IL-6), as well as plasma levels of soluble P-selectin and Endothelin-1 (ET-1), were analyzed.

Results: All platelet hyperactivity parameters were reduced significantly with the normalization of BP at the end of antihypertensive drug treatment (systolic/diastolic: 186.2 +/- 2.7/103.4 +/- 1.1 mm Hg vs 135.0 +/- 1.3/85.9 +/- 1.9 mm Hg; P < .001). Those factors more strictly associated with endothelium injury, such as ET-1 and IL-6, did not show variations. A significant correlation (Spearman Rank test) was observed among all platelet function parameters and blood pressure values.

Conclusions: This study demonstrated that even in a population of older hypertensive patients with no other risk factor for atherogenic disease, normalization of blood pressure induces a significant reduction of the parameters of enhanced platelet hyperactivity independent of the action exerted, at the platelet level, by the antihypertensive drugs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Antihypertensive Agents / therapeutic use*
  • Arteriosclerosis / etiology
  • Blood Pressure / drug effects*
  • Blood Pressure / physiology
  • Calcium Channel Blockers / therapeutic use
  • Endothelin-1 / blood
  • Female
  • Humans
  • Hypertension / complications
  • Hypertension / drug therapy
  • Hypertension / physiopathology*
  • Interleukin-1 / blood
  • Interleukin-6 / blood
  • Isoquinolines / therapeutic use
  • Male
  • Nifedipine / therapeutic use
  • P-Selectin / blood
  • Platelet Activation / drug effects
  • Platelet Activation / physiology*
  • Platelet Aggregation / drug effects
  • Platelet Aggregation / physiology
  • Prevalence
  • Prodrugs / therapeutic use
  • Quinapril
  • Tetrahydroisoquinolines*

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Calcium Channel Blockers
  • Endothelin-1
  • Interleukin-1
  • Interleukin-6
  • Isoquinolines
  • P-Selectin
  • Prodrugs
  • Tetrahydroisoquinolines
  • Nifedipine
  • Quinapril